Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality

BACKGROUND: Remdesivir is approved by the US Food and Drug Administration for the treatment of patients hospitalized with coronavirus disease 2019 (COVID-19) and has been shown to shorten time to recovery and improve clinical outcomes in randomized trials. METHODS: This was the final day 28 comparat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Olender, Susan A, Walunas, Theresa L, Martinez, Esteban, Perez, Katherine K, Castagna, Antonella, Wang, Su, Kurbegov, Dax, Goyal, Parag, Ripamonti, Diego, Balani, Bindu, De Rosa, Francesco G, De Wit, Stéphane, Kim, Shin-Woo, Diaz, George, Bruno, Raffaele, Mullane, Kathleen M, Lye, David Chien, Gottlieb, Robert L, Haubrich, Richard H, Chokkalingam, Anand P, Wu, George, Diaz-Cuervo, Helena, Brainard, Diana M, Lee, I-Heng, Hu, Hao, Lin, Lanjia, Osinusi, Anu O, Bernardino, Jose I, Boffito, Marta
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2021
Assuntos:
Major Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8244650/
https://ncbi.nlm.nih.gov/pubmed/34282406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofab278
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados